Skip to main
STTK

Shattuck Labs (STTK) Stock Forecast & Price Target

Shattuck Labs (STTK) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Shattuck Labs is a promising biotechnology company specializing in the development of innovative treatments for inflammatory and immune-mediated diseases, with a strong focus on developing a potentially first-in-class DR3 antagonist antibody for the treatment of IBD. With a well-established expertise in protein engineering, the company's lead asset SL-325 has shown impressive efficacy and safety signals in preclinical and clinical studies, positioning it as a potential best-in-class drug. Additionally, the company's diverse pipeline, including the recently disclosed bispecific candidate SL-846, presents significant potential for future growth. While risks exist, including the competitive landscape and financing requirements, we maintain a positive outlook on Shattuck Labs based on its promising pipeline, strong management team, and solid financial position, with operational runway through 2029.

Bears say

Shattuck Labs is currently developing potential treatments for inflammatory and immune-mediated diseases, including a first-in-class antibody for the treatment of inflammatory bowel disease. Despite promising data from a Phase 1 clinical trial, there are concerns regarding competition from other companies targeting the same pathway and the potential for the company's preclinical assets to successfully progress into clinical studies. Additionally, the company's valuation is based on a 6x multiple to estimated sales in 2035-2037, which is highly dependent on the future success of its drugs. These factors contribute to a negative outlook on the stock.

Shattuck Labs (STTK) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Shattuck Labs (STTK) Forecast

Analysts have given Shattuck Labs (STTK) a Buy based on their latest research and market trends.

According to 7 analysts, Shattuck Labs (STTK) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Shattuck Labs (STTK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.